Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pregabalin controlled release - Pfizer

Drug Profile

Pregabalin controlled release - Pfizer

Alternative Names: GRO 12 - Pfizer; Lyrica CR; MR-1- Pfizer; MR-2- Pfizer; Pregabalin CR; Pregabalin ER

Latest Information Update: 23 Oct 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Aminobutyric acids; Analgesics; Antiepileptic drugs; Anxiolytics; Gabapentinoids; Neuroprotectants; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Neuropathic pain; Postherpetic neuralgia
  • Phase III Fibromyalgia
  • No development reported Epilepsy

Most Recent Events

  • 31 Oct 2017 Pfizer expects launch of Pregabalin controlled release for Neuropathic pain associated with diabetic peripheral neuropathy in USA in January 2018
  • 12 Oct 2017 Registered for Neuropathic pain and Postherpetic neuralgia in USA (PO)
  • 12 Oct 2017 Updated efficacy and safety data from a phase III trial in Postherpetic neuralgia released by Pfizer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top